QNCX
Quince Therapeutics, Inc.
NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY
$1.31
+6.50% today
Updated 2026-04-30
Market cap
$20.05M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-16.80
Dividend yield
—
52W range
$1 – $46
Volume
63.6M
Quince Therapeutics, Inc. (QNCX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-9.83M | $-11.70M | $-33.28M | $-50.82M | $-62.93M | $-44.04M | $-18.29M | $-31.90M | $-41.42M |
| Capital expenditures | $77000.00 | $212000.00 | $55000.00 | $52000.00 | $180000.00 | $133000.00 | $160000.00 | $257000.00 | $352000.00 |
| Depreciation | $45000.00 | $51000.00 | $188000.00 | $332000.00 | $344000.00 | $204000.00 | $322000.00 | $186000.00 | — |
| Stock-based comp | $38000.00 | $155000.00 | $2.06M | $14.47M | $29.85M | $16.62M | $5.22M | $4.75M | $5.11M |
| Free cash flow | $-9.90M | $-11.91M | $-33.33M | $-50.87M | $-63.11M | $-44.17M | $-18.45M | $-32.16M | $-41.78M |
| Investing cash flow | $-77000.00 | $-46.75M | $-17.75M | $-52.43M | $58.95M | $18.00M | $-5.76M | $21.91M | — |
| Financing cash flow | $7.75M | $75.93M | $77.37M | $118.88M | $6.81M | $707000.00 | $143000.00 | $-4.78M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $-25.33M | — | — | — |